Acquired and Immune-Mediated Ataxias
Acquired ataxias encompass a heterogeneous group of cerebellar disorders arising from immune-mediated, toxic, nutritional, paraneoplastic, and degenerative etiologies. Unlike hereditary ataxias, these conditions are potentially treatable or preventable when identified early. Immune-mediated cerebellar ataxias (IMCAs) have received increasing recognition with the discovery of novel antibodies and the application of the 2021 PNS-Care diagnostic criteria. This article provides a comprehensive review of the major acquired and immune-mediated ataxias, with emphasis on antibody-tumor associations, pathogenic mechanisms, diagnostic workup, and evidence-based treatment for a medical professional audience.
Bottom Line
- Paraneoplastic cerebellar degeneration (PCD): Intracellular antibodies (anti-Yo, anti-Hu, anti-CV2) cause T-cell mediated, irreversible Purkinje cell destruction with poor immunotherapy response; cell-surface antibodies (anti-Tr/DNER, anti-mGluR1, anti-VGCC) have better treatment potential
- Anti-GAD65 cerebellar ataxia: Very high titers (>2,000 IU/mL, often >10,000) in the GAD-spectrum (overlapping with SPS and autoimmune epilepsy); subacute onset predicts better immunotherapy response than chronic progressive course
- Gluten ataxia: May account for up to 40% of sporadic idiopathic ataxias; anti-TG6 antibodies are more specific than anti-gliadin; strict gluten-free diet can halt or reverse progression if started before cerebellar atrophy
- Alcoholic cerebellar degeneration: The most common acquired ataxia; anterior vermis atrophy with predominantly gait ataxia; partially reversible with abstinence and nutritional repletion
- Drug-induced ataxia: Phenytoin, lithium, cytarabine, 5-FU, and methotrexate are the most common offenders; most are reversible with drug cessation, but chronic phenytoin and certain chemotherapeutics cause permanent damage
- Diagnostic imperative: All patients with unexplained progressive cerebellar ataxia require a systematic workup including paraneoplastic antibody panel (serum and CSF), nutritional markers, toxicology, and cancer screening guided by antibody profile
1. Paraneoplastic Cerebellar Degeneration (PCD)
Overview
Paraneoplastic cerebellar degeneration is a rare immune-mediated disorder in which tumor-associated autoimmunity targets cerebellar antigens, leading to subacute, progressive pancerebellar dysfunction. The 2021 updated PNS-Care diagnostic criteria (Graus et al.) classify PCD as a high-risk phenotype for underlying malignancy. A PNS-Care score ≥6 (combining clinical phenotype, antibody type, and cancer presence) yields a sensitivity of 93% and specificity of 100% for definite/probable PNS. Notably, up to 40% of patients with PCD are seronegative, and negative antibody testing does not exclude the diagnosis.
Key Pathogenic Principle: Intracellular vs Cell-Surface Antibodies
Clinical Pearl: Antibody Target Location Determines Treatment Response
- Intracellular antibodies (anti-Yo, anti-Hu, anti-CV2, anti-KLHL11): The autoantibodies cannot directly access their target in intact neurons. Pathogenesis is mediated by antigen-specific cytotoxic CD8+ T cells that recognize intracellular epitopes presented on MHC class I. This produces irreversible neuronal death with microglial nodules and inflammatory infiltrates. Immunotherapy has limited efficacy once damage is established.
- Cell-surface antibodies (anti-mGluR1, anti-Tr/DNER, anti-VGCC): Directly pathogenic through receptor internalization, complement activation, or disruption of synaptic transmission. Neuronal dysfunction may precede neuronal death, creating a therapeutic window where immunotherapy and tumor treatment can produce meaningful improvement.
- Practical implication: All PCD patients warrant aggressive tumor screening and early treatment, but expectations for neurological recovery differ substantially based on antibody type.
Paraneoplastic Antibody Profiles
| Antibody | Target (Location) | Associated Tumor | Clinical Features | Prognosis / Treatment Response |
|---|---|---|---|---|
| Anti-Yo (PCA-1) | CDR2, CDR2L (intracellular) | Ovarian, breast, uterine cancer | Most common PCD antibody; >90% women; mean age ~60; subacute pancerebellar syndrome with plateau within 6 months; T-cell mediated Purkinje cell destruction with microglial nodules, pSTAT1+ and CD8+ granzyme B+ T cells on neuropathology | Poor. Irreversible Purkinje cell loss; glucocorticoids appear ineffective; plasma exchange and rituximab may offer limited benefit; ofatumumab showed partial improvement in a 2024 case report; early tumor treatment offers the best chance for stabilization |
| Anti-Hu (ANNA-1) | HuD RNA-binding protein (intracellular) | Small cell lung cancer (SCLC); large cell neuroendocrine carcinoma | Most common overall paraneoplastic antibody; multifocal neurological involvement in 54%: sensory neuropathy/neuronopathy (60%), cerebellar ataxia (24%), limbic encephalitis (22%), brainstem dysfunction (22%); classic triad of encephalomyelitis + sensory neuropathy + cerebellar ataxia | Poor. Usually progressive despite treatment; early PET scan and tumor treatment may stabilize neurological disease; patients with PNS paradoxically have increased survival compared to SCLC patients without PNS, likely due to anti-tumor immunity; 5-year cancer screening recommended |
| Anti-Tr/DNER | Delta/Notch-like EGF-related receptor (cell surface) | Hodgkin lymphoma (HL) | Median age 52; 82% male; subacute onset in 93%; PCD antedates HL diagnosis in 80%; moderate CSF pleocytosis; MRI initially normal, later shows cerebellar atrophy; antibodies disappear spontaneously in all patients after successful HL treatment | Better than other PCD. Oncological complete response in 88% with standard HL chemotherapy (5-year OS 87%); neurological improvement in 41% of patients; responds to lymphoma treatment; IVIg + high-dose dexamethasone may provide additional neurological benefit; may relapse with lymphoma recurrence |
| Anti-CV2/CRMP5 | Collapsin response mediator protein 5 (intracellular) | SCLC (53%), thymoma (27%), other (20%) | High frequency of chorea + cerebellar ataxia; characteristic uveo/retinal symptoms (optic neuritis, posterior uveitis); peripheral neuropathy (80%); myelopathy; Lambert-Eaton myasthenic syndrome; accounts for <1% of neural autoantibodies tested in large laboratories | Variable. 4-year survival 66%; SCLC significantly associated with mortality (HR 18.18); thymoma not associated with mortality; moderate-severe disability (mRS 3–5) associated with CNS involvement (OR 7.0); myelopathy predicts wheelchair dependence (HR 7.57) |
| Anti-VGCC (P/Q type) | P/Q-type voltage-gated calcium channel (cell surface) | SCLC | Serum VGCC-positive in 41–44% of PCD patients (usually with SCLC co-occurrence); Lambert-Eaton myasthenic syndrome (LEMS) overlap in 20–40%; cerebellar ataxia + autonomic dysfunction; antibodies cause calcium dysregulation and altered synaptic transmission | Moderate. Unlike anti-Yo, the pathology shows neuronal dysfunction rather than purely T-cell mediated destruction; early oncologic and immunologic therapies may benefit; prolonged disease duration with positive response to treatment has been documented |
| Anti-KLHL11 | Kelch-like protein 11 (intracellular) | Testicular germ cell tumors (predominantly seminoma) | First described 2019; strong adult male predilection (all 39 patients in first 2 studies were male); distinctive presentation: hearing loss, tinnitus, and vertigo preceding cerebellar/brainstem signs by weeks to months; rhombencephalitis pattern; T2/FLAIR hyperintensity in temporal lobe (43%), cerebellum (32%), brainstem (11%); rare female cases now reported (breast, lung, Müllerian tumors) | Poor. Generally refractory to both immunotherapy and tumor treatment; FcRn inhibitor therapy showed response in a 2025 case report |
| Anti-mGluR1 | Metabotropic glutamate receptor 1 (cell surface) | Hodgkin lymphoma (~1/3 of tumor-associated cases) | Rare; cerebellar ataxia is the dominant presentation (85%); dysarthria (40%), behavioral changes (35%), cognitive impairment (22.5%); tumors identified in ~22.5%; in HL, lymphoma may precede ataxia by months to years, and ataxia can occur during prolonged complete remission | Variable. Early immunotherapy associated with better outcomes; cell-surface antibody with direct pathogenic potential; favorable prognosis group had higher rates of first-line immunotherapy |
Cancer Screening Protocols for PCD
Antibody-Guided Tumor Screening
| Antibody | Primary Tumor | Recommended Screening | Follow-up if Negative |
|---|---|---|---|
| Anti-Yo (PCA-1) | Ovarian, breast, uterine | CT chest/abdomen/pelvis; mammography; pelvic MRI or transvaginal US; PET-CT | Repeat every 6 months for 4 years |
| Anti-Hu (ANNA-1) | SCLC | CT chest; whole-body PET-CT (early implementation recommended) | Repeat every 6 months for 5 years |
| Anti-Tr/DNER | Hodgkin lymphoma | CT chest/abdomen/pelvis; PET-CT | Repeat every 6 months for 2–4 years; can relapse >12 years later |
| Anti-CV2/CRMP5 | SCLC, thymoma | CT chest/abdomen/pelvis; PET-CT | Repeat every 6 months for 4 years |
| Anti-VGCC (P/Q) | SCLC | CT chest; PET-CT; EMG/repetitive nerve stimulation for LEMS | Repeat every 6 months for 2–4 years |
| Anti-KLHL11 | Testicular germ cell tumor | Testicular ultrasound; CT abdomen/pelvis | Ongoing surveillance; consider retroperitoneal seminoma |
| Anti-mGluR1 | Hodgkin lymphoma | CT chest/abdomen/pelvis; PET-CT | Ongoing surveillance recommended even after HL remission |
Key principle: Whole-body FDG-PET/CT should be considered when conventional imaging is negative but a high-risk paraneoplastic antibody is detected. Cancer may become apparent months to years after neurological presentation.
2. Anti-GAD65 Cerebellar Ataxia
Overview
Anti-GAD65 cerebellar ataxia is predominantly a non-paraneoplastic autoimmune cerebellar ataxia that occurs as part of the broader GAD65 antibody-spectrum disorders, which also includes stiff person syndrome (SPS), autoimmune epilepsy, and limbic encephalitis. It is characterized by very high GAD65 antibody titers, slowly progressive or subacute cerebellar dysfunction, and frequent association with other organ-specific autoimmune diseases.
Diagnostic Criteria and Key Features
| Feature | Details |
|---|---|
| Antibody titers | Very high: typically >2,000 IU/mL, often >10,000 IU/mL by ELISA; low-titer GAD65 positivity (as seen in 2–4% of type 1 diabetes patients) does not indicate neurological disease |
| Demographics | Predilection for women in their 50s–60s; female predominance |
| Onset pattern | Subacute onset (39%) or chronic progressive (61%); onset type is a critical prognostic factor |
| Clinical presentation | Slowly progressive cerebellar ataxia (gait > limb); downbeat nystagmus is characteristic; may have concomitant SPS features (stiffness, spasms) or epilepsy |
| CSF findings | Oligoclonal bands in 63–100%; intrathecal GAD65 antibody synthesis (low serum:CSF ratio consistent with intrathecal production in 12/19 tested patients); normal to mildly elevated protein and cell count |
| MRI | May be normal early in the course; cerebellar atrophy develops over time and correlates with worse prognosis; atrophy at presentation predicts poor immunotherapy response |
| Paraneoplastic association | Rarely paraneoplastic; low titers may occasionally be seen with thymoma; routine cancer screening not required for high-titer GAD65 unless atypical features present |
GAD65-Spectrum Overlap
The GAD65 Antibody Spectrum
GAD65 antibodies at neurologically significant titers can produce overlapping clinical syndromes:
- Stiff person syndrome (SPS): Axial rigidity, episodic painful spasms, hyperekplexia; GAD65 positive in 80–85%
- Cerebellar ataxia: Progressive gait and limb ataxia, downbeat nystagmus
- Autoimmune epilepsy: Drug-resistant temporal lobe epilepsy
- Limbic encephalitis: Memory impairment, psychiatric symptoms, seizures
- Overlap phenotypes: SPS + cerebellar ataxia; epilepsy + ataxia; all four combined
Concurrent systemic autoimmunity is documented in 59% of patients with GAD65 neurological autoimmunity: thyroid disease (34%), type 1 diabetes mellitus (30%), pernicious anemia (19%).
Treatment
| Therapy | Evidence | Key Points |
|---|---|---|
| IVIg | Most commonly used first-line immunotherapy | Improvement in some patients; one patient transitioned from wheelchair to walker with IVIg; maintenance dosing may be required |
| IV methylprednisolone | Frequently used in induction | Often combined with other agents; variable response |
| Rituximab | Second-line for IVIg non-responders | May stabilize or improve GAD-antibody cerebellar ataxia; benefit may take months to manifest |
| Plasma exchange | Used in acute/subacute cases | Included in aggressive induction protocols |
| Maintenance (oral) | Azathioprine, mycophenolate mofetil, oral prednisolone | Used after induction to maintain remission; long-term data limited |
Prognostic Factors in Anti-GAD65 Cerebellar Ataxia
- Subacute onset: 67% responsive to immunotherapy
- Chronic progressive onset: Only 14% responsive to immunotherapy
- Absence of cerebellar atrophy on MRI: Better treatment response
- Presence of cerebellar atrophy: Suggests irreversible Purkinje cell loss; poor treatment response
- GAD-antibody titers >10,000 IU/mL, intrathecal synthesis, and oligoclonal bands do not independently predict treatment response
- Early treatment before establishment of atrophy is the most decisive factor
3. Gluten Ataxia
Overview
Gluten ataxia, first defined by Hadjivassiliou et al., is a sporadic cerebellar ataxia triggered by gluten sensitivity, with or without gastrointestinal symptoms or classic celiac disease. It is a controversial but increasingly recognized entity, and has been proposed as the single most common cause of sporadic idiopathic ataxia in some series.
Epidemiology and Controversy
- Prevalence: Accounts for approximately 15% of all ataxia cases and up to 40% of idiopathic sporadic ataxias in Sheffield, UK, cohorts (Hadjivassiliou et al.)
- Anti-gliadin antibody (AGA) prevalence: Varies between 12–41% in ataxia populations depending on the subtype studied
- Gluten enteropathy (celiac disease): Diagnosed in 24% of tested ataxia patients positive for gluten-related antibodies
- Mean age of onset: Approximately 53 years; slight male predominance
- Diagnostic controversy: The specificity of anti-gliadin antibodies (IgA and IgG) has been questioned, as they can be found in healthy individuals; anti-TG6 antibodies are emerging as a more specific marker
- Can occur without GI symptoms: Many patients have no gastrointestinal complaints or villous atrophy (extraintestinal celiac disease or non-celiac gluten sensitivity)
Antibodies and Pathogenesis
| Antibody | Details | Clinical Utility |
|---|---|---|
| Anti-gliadin IgA and IgG | Classic screening markers; IgG anti-gliadin is more common than IgA in neurological presentations | Sensitive but not specific; present in healthy controls and other conditions; useful as initial screen |
| Anti-TG2 (tissue transglutaminase 2) | Standard celiac disease marker; targets intestinal TG2 | High specificity for celiac disease but may be negative in purely neurological gluten sensitivity |
| Anti-TG6 (tissue transglutaminase 6) | TG6 is predominantly expressed in the brain; IgA anti-TG6 antibodies produced in the gut may cross a dysfunctional blood-brain barrier; gluten-dependent (disappear with gluten-free diet) | Emerging as the most sensitive and specific marker for gluten ataxia; 2025 CSF studies demonstrate intrathecal anti-TG6 IgA contributing to cerebellar degeneration; prevalence ~11% in celiac disease with CNS involvement |
| Anti-endomysial antibodies (EMA) | Highly specific for celiac disease | May be negative in patients without villous atrophy; positive result strongly supports celiac disease |
Clinical Features
- Predominant gait ataxia (cerebellar vermis involvement); limb ataxia and dysarthria less prominent initially
- Peripheral neuropathy is common (sensory axonal or mixed)
- Gaze-evoked nystagmus and other oculomotor abnormalities
- MRI: Cerebellar atrophy (particularly vermis) in advanced cases; may be normal early in the disease
- Absent GI symptoms in a significant proportion of patients
Treatment
Gluten-Free Diet: The Primary Treatment
- Strict gluten-free diet (GFD) is the recommended first-line treatment
- Antibody elimination typically requires 6–12 months of strict adherence
- Early treatment is critical: Loss of Purkinje cells is irreversible; treatment must begin before the development of cerebellar atrophy
- Response to GFD: Stabilization or improvement of ataxia, particularly if initiated early; patients with established atrophy may stabilize but are less likely to improve
- Monitoring: Serial antibody testing (anti-gliadin, anti-TG6 if available) to confirm dietary adherence; repeat MRI to assess for progressive atrophy
- Specialist dietician review is recommended for all patients commencing GFD
Recommended Screening Protocol
All patients presenting with idiopathic progressive cerebellar ataxia should be screened with:
- Anti-gliadin IgG and IgA
- Anti-endomysial antibodies (EMA)
- Anti-tissue transglutaminase 2 (TG2)
- Anti-tissue transglutaminase 6 (TG6) — if available
Patients positive for any of these antibodies with no alternative cause for their ataxia should be offered a strict gluten-free diet with regular follow-up.
4. Steroid-Responsive Encephalopathy with Autoimmune Thyroiditis (SREAT)
Overview
SREAT, also known as Hashimoto encephalopathy, is a controversial and poorly understood condition characterized by encephalopathy in the setting of elevated anti-thyroid antibodies, responsiveness to corticosteroids, and exclusion of alternative diagnoses. Although the hallmark presentation is a non-specific encephalopathy with altered mental status, cerebellar ataxia can be a prominent or, rarely, the predominant manifestation.
Key Features
| Feature | Details |
|---|---|
| Antibodies | Elevated anti-thyroid peroxidase (anti-TPO) and/or anti-thyroglobulin (anti-Tg) in serum; anti-TPO is more commonly positive; these antibodies are likely epiphenomena rather than directly pathogenic |
| Clinical presentation | Encephalopathy (confusion to coma); seizures; movement disorders (myoclonus, tremor); psychosis; cerebellar ataxia (uncommon as primary manifestation, rare as sole manifestation) |
| Thyroid function | Variable — may be euthyroid, hypothyroid, or hyperthyroid; thyroid status does not correlate with neurological severity |
| Diagnostic criteria | Diagnosis of exclusion: (1) compatible encephalopathy, (2) elevated anti-TPO or anti-Tg, (3) exclusion of infective, inflammatory, other autoimmune, and neoplastic etiologies, (4) absence of well-characterized neuronal antibodies in serum and CSF |
| CSF | Elevated protein in some; may have mild pleocytosis; anti-TPO may be detected in CSF |
| MRI | Often normal; nonspecific white matter changes in some |
Treatment
- First-line: IV methylprednisolone 1 g/day for 3–7 days, followed by oral prednisone taper (50–150 mg/day)
- Steroid-responsive: The diagnosis is strongly supported by a good clinical response to corticosteroids
- Steroid-refractory: Azathioprine, cyclophosphamide, methotrexate, IVIg, or plasma exchange
- Prognosis: Generally favorable with treatment; relapses may occur with steroid taper
5. Opsoclonus-Myoclonus-Ataxia Syndrome (OMS)
Overview
Opsoclonus-myoclonus-ataxia syndrome is a rare neuroinflammatory disorder of paraneoplastic, parainfectious, or idiopathic origin, characterized by involuntary chaotic conjugate eye movements (opsoclonus), diffuse myoclonus, cerebellar ataxia, and often behavioral and sleep disturbance. Incidence is estimated at approximately 1 in 10 million per year.
Etiology by Age Group
| Population | Etiology | Key Details |
|---|---|---|
| Children | Neuroblastoma (50–80%); ganglioneuroblastoma; post-infectious (viral) | OMS occurs in ~3% of all neuroblastomas; tumors are typically small and well-differentiated with favorable oncological prognosis; paradoxically, neuroblastoma with OMS has better oncological outcome than without, likely due to immune-mediated tumor suppression |
| Adults | Breast cancer; small cell lung cancer (SCLC); ovarian cancer; post-infectious (viral); idiopathic | Paraneoplastic etiology more common than in children; broader tumor spectrum; specific antibody biomarkers generally not identified |
| Post-infectious | Viral (EBV, CMV, enterovirus, others); post-vaccination (rare) | May occur at any age; generally better prognosis; self-limited in some cases |
Treatment
OMS Treatment Approach
- Tumor resection: Essential when tumor is identified; improves neurological and oncological outcomes
- FLAIR protocol (National Pediatric Myoclonus Center): Front-loaded high-dose ACTH + IVIg + rituximab — best-documented outcomes; 80–90% response rate; relapse rate approximately 20%
- Individual agents:
- ACTH / corticosteroids: First-line; high-dose ACTH preferred in children
- IVIg: Second agent in combination protocols
- Rituximab: Effective in conventional treatment-resistant cases; evidence from case series
- Cyclophosphamide: Reserved for refractory cases
- Long-term neurological sequelae: Cognitive and behavioral deficits (especially in children) are common despite treatment; motor recovery is generally better than cognitive recovery
6. Alcoholic Cerebellar Degeneration
Overview
Alcoholic cerebellar degeneration (ACD) is the most common acquired cerebellar ataxia worldwide. It results from the combined effects of ethanol neurotoxicity, thiamine deficiency, and potentially immune-mediated mechanisms. Pathologically, it is characterized by selective degeneration of the anterior superior cerebellar vermis with preferential loss of Purkinje cells.
Epidemiology
- Prevalence: Estimated at 27–42% of chronic alcoholics in autopsy studies; histologically verified superior vermis atrophy found in 42% of alcoholics vs. 9% of controls
- Clinical prevalence: Lower than pathological prevalence, suggesting subclinical disease is common
Clinical Features
| Feature | Details |
|---|---|
| Gait ataxia | The predominant and often sole manifestation; wide-based, unsteady gait; tandem walking impaired; reflects anterior vermis pathology |
| Limb ataxia | Lower extremities affected more than upper; finger-to-nose may be relatively spared; reflects anterior lobe > posterior lobe involvement |
| Dysarthria | Typically mild or absent (unlike PCD) |
| Onset | Usually insidious over weeks to months; may present acutely (often superimposed on Wernicke encephalopathy) |
| Associated features | Peripheral neuropathy (common); cognitive impairment; hepatic dysfunction; nutritional deficiencies |
| MRI | Anterior vermis atrophy is the hallmark; cerebellar hemispheres relatively spared early; cortical atrophy may be seen |
Pathogenesis
- Direct ethanol toxicity: Purkinje cell, granule cell, and white matter degeneration
- Thiamine deficiency: Overlaps with Wernicke encephalopathy; many patients have combined pathology
- Immune-mediated mechanisms: Recent evidence suggests possible immune-mediated contribution beyond direct toxicity, though this remains under investigation
Treatment and Reversibility
- Alcohol abstinence: Essential; improvement varies with degree of abstinence and severity of disease
- Nutritional supplementation: Thiamine (vitamin B1), folate, and comprehensive nutritional repletion
- Reversibility: Partially reversible with abstinence and nutrition — tissue shrinkage without permanent cell loss may represent recovery potential, whereas established Purkinje cell death produces irreversible deficits
- Gait rehabilitation: Physical therapy for gait optimization; balance training
- Prognosis: Gait ataxia can be persistent in severe cases despite abstinence; early intervention offers the best outcomes
7. Drug-Induced Cerebellar Ataxia
Overview
Drug-induced cerebellar ataxia is an important and potentially preventable cause of acquired ataxia. The majority of drug-induced ataxias completely resolve with cessation of the offending agent, though some drugs — particularly with chronic use — can produce irreversible cerebellar damage.
Major Offending Agents
| Drug | Mechanism / Clinical Features | Reversibility |
|---|---|---|
| Phenytoin | Most common drug-induced cerebellar ataxia; nystagmus at therapeutic doses; ataxia at supratherapeutic levels; chronic toxicity causes Purkinje cell loss and cerebellar atrophy visible on MRI | Acute toxicity: Usually reversible with dose reduction Chronic toxicity: May cause permanent cerebellar atrophy and irreversible ataxia |
| Lithium | Cerebellar ataxia at toxic levels; chronic lithium use may cause persistent cerebellar dysfunction | Variable: Acute toxicity often reversible; persistent symptoms described with chronic exposure; may leave permanent deficits |
| Cytarabine (Ara-C) | Acute cerebellar syndrome is the most common neurotoxic profile; occurs particularly with high-dose regimens (>3 g/m²); pancerebellar syndrome with gait and limb ataxia, dysarthria, nystagmus | Variable: May be reversible if recognized early and drug is stopped; permanent damage occurs in a proportion of cases, especially at high cumulative doses |
| 5-Fluorouracil (5-FU) | Acute cerebellar syndrome; rare but serious; patients with dihydropyrimidine dehydrogenase (DPD) deficiency at increased risk | Variable: Usually reversible; irreversible cerebellar ataxia reported in some cases |
| Methotrexate | Particularly with intrathecal administration; can cause leukoencephalopathy and cerebellar dysfunction; may coexist with reversible cerebral neurotoxicity and irreversible cerebellar atrophy | Variable: Cerebral changes may be reversible while cerebellar damage may be permanent |
| Carbamazepine | Dose-related ataxia, nystagmus, diplopia at supratherapeutic levels | Usually reversible with dose reduction |
| Amiodarone | Tremor and ataxia; peripheral neuropathy more common; may occur at therapeutic levels with chronic use | Usually reversible with drug discontinuation |
| Valproate | Tremor more common than ataxia; cerebellar dysfunction with chronic use | Usually reversible |
Clinical Pearl: Reversibility Depends on Duration
Prolonged exposure to neurotoxic drugs may produce cerebellar degeneration that is not reversible, even after drug cessation. The key distinction is between acute/subacute toxicity (generally reversible) and chronic toxicity with established Purkinje cell loss (potentially permanent). Always obtain MRI to assess for cerebellar atrophy when persistent ataxia follows drug exposure.
8. Nutritional Deficiency Ataxias
8.1 Wernicke Encephalopathy (Thiamine / Vitamin B1 Deficiency)
| Feature | Details |
|---|---|
| Classic triad | Altered consciousness (80%), ocular abnormalities (77%), and ataxia (54%); the complete triad is present in only 16–38% of cases |
| Ataxia features | Wide-based gait ataxia; truncal instability; may range from mild gait unsteadiness to inability to stand or walk |
| Ocular signs | Horizontal nystagmus (most common), abducens (VI) palsy, conjugate gaze palsy, complete ophthalmoplegia |
| Etiologies | Chronic alcoholism (most common); hyperemesis gravidarum; bariatric surgery; prolonged IV glucose without thiamine; anorexia nervosa; cancer chemotherapy |
| MRI findings | Symmetric T2/FLAIR hyperintensities in mammillary bodies, medial thalami, periaqueductal gray, and tectal plate; sensitivity ~50%, specificity ~90%; MRI may normalize rapidly after thiamine initiation |
| Treatment | Parenteral thiamine immediately: IV thiamine 200–500 mg TID for 3–5 days, then oral maintenance; ataxia and ophthalmoplegia usually resolve briskly (hours to days) if treated early; must give thiamine BEFORE glucose (glucose oxidation depletes thiamine and can precipitate Wernicke) |
| Prognosis | Reversible if treated early; delayed treatment leads to Korsakoff syndrome (irreversible anterograde amnesia) in up to 80% of untreated survivors |
8.2 Vitamin B12 Deficiency
- Subacute combined degeneration: Posterior column (dorsal column) and lateral corticospinal tract demyelination; sensory ataxia from proprioceptive loss
- Clinical features: Sensory ataxia (positive Romberg sign), impaired vibration and proprioception, spastic paraparesis, peripheral neuropathy; cognitive impairment possible
- Diagnosis: Serum B12, methylmalonic acid (elevated), homocysteine (elevated); MRI spine may show dorsal column T2 hyperintensity (“inverted V sign”)
- Treatment: Parenteral vitamin B12 (IM cyanocobalamin 1000 mcg daily for 7 days, then weekly for 4 weeks, then monthly); neurological improvement depends on duration and severity before treatment
8.3 Vitamin E Deficiency
| Form | Mechanism | Clinical Features | Treatment |
|---|---|---|---|
| Acquired vitamin E deficiency | Fat malabsorption (cholestasis, pancreatic insufficiency, short bowel syndrome, abetalipoproteinemia) | Progressive ataxia, peripheral neuropathy, retinitis pigmentosa, myopathy | Vitamin E supplementation; treat underlying cause |
| AVED (Ataxia with Vitamin E Deficiency) | Autosomal recessive mutations in TTPA gene (alpha-tocopherol transfer protein); impaired hepatic retention and distribution of dietary vitamin E | Originally termed “Friedreich ataxia phenotype with selective vitamin E deficiency” — closely resembles Friedreich ataxia: progressive ataxia, clumsiness, loss of proprioception, areflexia; onset typically age 5–15; axonal dystrophy with spinocerebellar and posterior column degeneration | Lifelong high-dose vitamin E supplementation (800–1500 IU/day); if initiated in presymptomatic individuals, manifestations do not develop; early treatment can stabilize or improve neurological function |
Clinical Pearl: AVED vs Friedreich Ataxia
AVED and Friedreich ataxia share nearly identical clinical features (progressive ataxia, areflexia, proprioceptive loss, cardiomyopathy in some). However, AVED is treatable with vitamin E supplementation. Serum vitamin E should be checked in all patients with a Friedreich-like phenotype, as AVED is a “never to be missed” diagnosis. The key distinguishing feature: Friedreich ataxia is not associated with vitamin E deficiency.
9. Superficial Siderosis
Overview
Superficial siderosis (SS) of the central nervous system is a slowly progressive neurodegenerative condition caused by chronic or repeated subarachnoid hemorrhage leading to subpial hemosiderin deposition on the surfaces of the brain, brainstem, cerebellum, and spinal cord. Iron-mediated free radical damage causes progressive neuronal injury, particularly affecting the cerebellum and vestibulocochlear nerves.
Clinical Triad
Classic Triad of Superficial Siderosis
- Sensorineural hearing loss: ~95% of patients; bilateral, progressive; often the earliest symptom; results from hemosiderin deposition on the vestibulocochlear (CN VIII) nerve due to its long intracisternal course
- Cerebellar ataxia: ~88%; progressive wide-based gait, balance impairment; reflects cerebellar surface hemosiderin deposition
- Myelopathy: ~76%; pyramidal signs (spasticity, hyperreflexia, Babinski sign); reflects spinal cord surface deposition
Diagnosis
| Investigation | Findings |
|---|---|
| MRI (T2*/GRE or SWI sequences) | The diagnostic study of choice: characteristic rim of low signal (hypointensity) coating the surface of the brain, brainstem, cerebellum, and/or spinal cord on T2*-weighted, gradient-echo (GRE), or susceptibility-weighted imaging (SWI) sequences; reflects paramagnetic hemosiderin |
| Conventional MRI (T2/FLAIR) | May show low signal along CNS surfaces; less sensitive than T2*/GRE/SWI |
| CSF analysis | Xanthochromia; elevated ferritin; siderophages may be present |
| Audiometry | High-frequency sensorineural hearing loss progressing to bilateral deafness |
| Source identification | Spinal MRI, CT myelography, or digital subtraction angiography to identify bleeding source (dural defect, vascular malformation, tumor); source identified in ~50–70% of cases |
Etiologies
- Often idiopathic (~35%)
- Post-surgical or post-traumatic (prior spinal/CNS surgery, head/spine trauma)
- Dural defects (CSF leak sites acting as conduits for subarachnoid bleeding)
- Vascular malformations (AVM, cavernoma)
- CNS tumors (ependymoma, particularly of the cauda equina)
- Brachial plexus/nerve root avulsion
Treatment
- Source treatment: Surgical repair of identifiable bleeding source (dural defect repair, tumor resection, AVM obliteration) is the most important intervention to prevent ongoing hemosiderin deposition
- Chelation therapy (deferiprone): An iron chelator that crosses the blood-brain barrier; some evidence of radiographic improvement; however, routine use is not currently recommended due to insufficient evidence of clinical benefit and risks (agranulocytosis)
- Cochlear implantation: Has shown some benefit for hearing loss, though sustained benefit is variable; referral to otologist is reasonable
- Rehabilitation: Physical and occupational therapy for gait ataxia, balance, and pyramidal symptoms
- Prognosis: Deficits are often irreversible; progressive without source control; early identification and treatment of the bleeding source is key
10. Comprehensive Diagnostic Workup
Recommended Investigations for Acquired/Immune-Mediated Ataxia
| Category | Tests | Key Considerations |
|---|---|---|
| Blood — Immune/Autoimmune | Anti-GAD65 antibodies (ELISA, quantitative); anti-gliadin IgA/IgG; anti-TG2; anti-TG6 (if available); anti-TPO and anti-thyroglobulin; comprehensive paraneoplastic antibody panel (anti-Yo, anti-Hu, anti-Tr/DNER, anti-CV2/CRMP5, anti-VGCC, anti-KLHL11, anti-mGluR1, anti-amphiphysin); ANA, anti-dsDNA | Panel testing recommended over sequential testing due to phenotypic overlap; cell-based assays preferred; test both serum and CSF for paraneoplastic antibodies |
| Blood — Nutritional / Metabolic | Thiamine (B1); vitamin B12, methylmalonic acid, homocysteine; vitamin E (alpha-tocopherol); folate; copper and ceruloplasmin; zinc | Thiamine and B12 deficiency are treatable causes; vitamin E deficiency mimics Friedreich ataxia; copper deficiency (from zinc excess or malabsorption) causes myeloneuropathy and ataxia |
| Blood — Infectious / Other | RPR/VDRL (neurosyphilis); HIV; hepatitis panel; TSH; CBC, CMP; ESR, CRP; heavy metals (lead, mercury, thallium); alcohol level; HgbA1c | Neurosyphilis (tabes dorsalis) causes sensory ataxia; HIV can cause cerebellar dysfunction; heavy metal toxicity is rare but treatable |
| Cerebrospinal Fluid | Cell count with differential; protein; glucose; oligoclonal bands; IgG index; cytology; GAD65 antibodies (CSF); paraneoplastic antibodies (CSF); 14-3-3 protein and RT-QuIC (if prion disease suspected); VDRL; cultures if infectious etiology considered | Inflammatory CSF (pleocytosis, oligoclonal bands, elevated IgG) supports autoimmune etiology; intrathecal antibody synthesis has diagnostic significance for GAD65 and paraneoplastic disorders; cytology to exclude CNS lymphoma/carcinomatosis |
| Neuroimaging — Brain MRI | T1, T2/FLAIR, DWI, post-contrast, T2*/GRE or SWI |
Pattern recognition: • Anterior vermis atrophy → alcoholic cerebellar degeneration • Diffuse cerebellar atrophy → PCD, chronic anti-GAD65 ataxia • Mammillary body/periaqueductal T2 hyperintensity → Wernicke encephalopathy • Hemosiderin rim on T2*/SWI → superficial siderosis • Normal early MRI → does not exclude PCD or immune-mediated ataxia • Dorsal column T2 hyperintensity (spine) → B12 deficiency |
| Cancer Screening | CT chest/abdomen/pelvis; whole-body FDG-PET/CT; mammography; pelvic MRI or transvaginal US; testicular US | Guided by antibody type (see PCD section); PET-CT if conventional imaging negative but high-risk antibody present; repeat every 6 months for 2–5 years for high-risk paraneoplastic antibodies; cancer may be occult at neurological presentation |
| Electrophysiology | EMG/NCS; repetitive nerve stimulation (if LEMS suspected) | Assess for peripheral neuropathy (common in gluten ataxia, B12 deficiency, anti-Hu); decremental response at low-frequency and incremental at high-frequency RNS in LEMS (anti-VGCC) |
| Genetic Testing | TTPA gene sequencing (if AVED suspected); expanded ataxia gene panel (if hereditary ataxia not excluded) | Consider genetic testing when acquired causes have been excluded; AVED is treatable and must not be missed; some hereditary ataxias present in adulthood |
MRI Pattern Recognition
| MRI Finding | Primary Differential Diagnoses |
|---|---|
| Anterior vermis atrophy | Alcoholic cerebellar degeneration; chronic phenytoin toxicity |
| Diffuse/pancerebellar atrophy | PCD (anti-Yo, anti-Hu); chronic anti-GAD65 ataxia; MSA-C; hereditary ataxias |
| Mammillary body T2 hyperintensity | Wernicke encephalopathy (thiamine deficiency) |
| Periaqueductal/medial thalamic T2 signal | Wernicke encephalopathy |
| T2*/SWI surface hypointensity (hemosiderin rim) | Superficial siderosis |
| Dorsal column T2 hyperintensity (spinal cord) | Vitamin B12 deficiency (subacute combined degeneration); copper deficiency |
| Medial temporal T2/FLAIR hyperintensity | Limbic encephalitis (anti-GAD65, anti-Hu, other) |
| Brainstem/cerebellar T2 hyperintensity | Anti-KLHL11 rhombencephalitis; demyelinating disease; acute cerebellitis |
| Normal MRI with progressive ataxia | Early PCD (any antibody); early immune-mediated ataxia; gluten ataxia (early); drug-induced; paraneoplastic (seronegative) |
Stepwise Diagnostic Algorithm
Approach to Unexplained Progressive Cerebellar Ataxia
- Exclude common acquired causes: Alcohol history, medication review (phenytoin, lithium, chemotherapy), nutritional assessment (B1, B12, vitamin E, folate)
- Baseline investigations: CBC, CMP, TSH, RPR, HIV, HgbA1c, B12/MMA, thiamine, vitamin E, copper/ceruloplasmin
- Autoimmune serologies: Anti-GAD65 (quantitative), anti-gliadin IgA/IgG, anti-TG2, anti-TG6 (if available), anti-TPO
- Paraneoplastic antibody panel: Comprehensive panel in both serum AND CSF (anti-Yo, anti-Hu, anti-Tr/DNER, anti-CV2/CRMP5, anti-VGCC, anti-KLHL11, anti-mGluR1, anti-amphiphysin)
- CSF analysis: Cell count, protein, glucose, oligoclonal bands, IgG index, cytology, antibodies
- Brain MRI: T1, T2/FLAIR, DWI, T2*/SWI, post-contrast; spine MRI if myelopathic signs
- Cancer screening: Guided by antibody profile; whole-body PET-CT if high-risk antibody positive with negative conventional imaging
- If all negative: Consider genetic testing (expanded ataxia panel, TTPA); repeat antibody testing in 3–6 months (seroconversion may occur); repeat cancer screening for 2–5 years
References
- Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2021;8(4):e1014. doi: 10.1212/NXI.0000000000001014
- Venkatraman A, Bhanu M. Paraneoplastic cerebellar degeneration with anti-Yo antibodies — a review. Ann Clin Transl Neurol. 2016;3(8):655–663. doi: 10.1002/acn3.328
- Hoftberger R, Rosenfeld MR, Dalmau J. Update on neurological paraneoplastic syndromes. Curr Opin Oncol. 2015;27(6):489–495.
- Dubey D, Wilson MR, Engstrom JW, et al. Clinical significance of Kelch-like protein 11 antibodies. Neurol Neuroimmunol Neuroinflamm. 2020;7(3):e666. doi: 10.1212/NXI.0000000000000666
- Uysal SP, Lennon VA, Engel AG, et al. Predicting disability and mortality in CV2/CRMP5-IgG associated paraneoplastic neurologic disorders. Ann Clin Transl Neurol. 2024;11(3):649–660. doi: 10.1002/acn3.51991
- Sillevis Smitt P, Kinoshita A, De Leeuw B, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med. 2000;342(1):21–27. doi: 10.1056/NEJM200001063420104
- Ariño H, Gresa-Arribas N, Blanco Y, et al. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy. JAMA Neurol. 2014;71(8):1009–1016. doi: 10.1001/jamaneurol.2014.1011
- McKeon A. GAD antibodies in neurological disease: a critical evaluation of the utility and treatment implications. J Neurol. 2025. doi: 10.1007/s00415-025-12926-3
- Hadjivassiliou M, Sanders DS, Woodroofe N, et al. Gluten ataxia. Cerebellum. 2008;7(3):494–498.
- Hadjivassiliou M, Aeschlimann P, Sanders DS, et al. Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. Neurology. 2013;80(19):1740–1745. doi: 10.1212/WNL.0b013e3182919070
- Hadjivassiliou M, et al. CSF markers of TG6 autoimmunity in gluten ataxia. Cerebellum. 2025. doi: 10.1007/s12311-025-01693-5
- Laurent C, Dieterich M, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. JAMA Neurol. 2016;73(11):1288–1297.
- Pranzatelli MR. Opsoclonus-myoclonus-ataxia syndrome. UpToDate. 2024.
- Shanmugarajah PD, Hoggard N, Currie S, et al. Alcohol-related cerebellar degeneration: not all down to toxicity? Cerebellum Ataxias. 2016;3:17. doi: 10.1186/s40673-016-0055-1
- Torvik A, Torp S, Lindboe CF. The prevalence of alcoholic cerebellar atrophy: a morphometric and histological study of an autopsy material. J Neurol Sci. 1986;75(1):43–51.
- van Gaalen J, Kerstens FG, Blom JD, et al. Drug-induced cerebellar ataxia: a systematic review. CNS Drugs. 2014;28(12):1139–1153. doi: 10.1007/s40263-014-0200-4
- Galvin R, Brathen G, Ivashynka A, et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol. 2010;17(12):1408–1418.
- El Euch-Fayache G, et al. Ataxia with vitamin E deficiency. In: GeneReviews. NCBI Bookshelf. Updated 2023. NBK1241.
- Levy M, Turtzo C, Llinas RH. Superficial siderosis: a case report and review of the literature. Nat Clin Pract Neurol. 2007;3(1):54–58.
- Mitoma H, Hadjivassiliou M, Honnorat J. Guidelines for treatment of immune-mediated cerebellar ataxias. Cerebellum Ataxias. 2015;2:14. doi: 10.1186/s40673-015-0034-y
- Joubert B, Honnorat J. Immune-mediated cerebellar ataxias: practical guidelines and therapeutic challenges. Curr Opin Neurol. 2019;32(3):346–352.